Low-Dose Atropine Eye Drops Show Promise in Slowing Childhood Myopia, AIIMS Study Finds

A recent study conducted by the All India Institute of Medical Sciences (AIIMS), Bibinagar, Telangana, has demonstrated that low-dose atropine eye drops, specifically at a 0.05% concentration, effectively slow the progression of myopia in children. This development holds significant promise in managing the global rise of myopia—a refractive eye condition affecting millions of children and substantially increasing the risk of vision complications later in life.

What Was Found?

The AIIMS Bibinagar study, a randomized clinical trial involving 272 children aged 5 to 16 years with myopia between -1.0 to -6.0 diopters (D) and documented annual progression greater than 0.5 D, compared the efficacy and safety of 0.01% atropine, 0.05% atropine, and placebo eye drops over one year. Key findings include:

• The 0.05% atropine group showed significantly slower myopia progression with an average refractive increase of 0.263 D compared to 0.759 D in the placebo group.

• Axial length elongation—a key factor in worsening myopia—was reduced to 0.138 mm in the 0.05% group versus 0.367 mm in placebo.

• The 0.01% atropine group saw a moderate but less pronounced slowing of progression (0.319 D refractive change).

• Side effects such as mild pupil dilation and near vision difficulty were observed more with 0.05% atropine but were generally well tolerated without affecting daily tasks or treatment compliance.

Expert Perspectives

Dr. Anil Kumar, a pediatric ophthalmologist not involved in the study, commented, “The findings reinforce that low-dose atropine, particularly 0.05%, balances efficacy and safety, making it a viable option for myopia control in children. This is especially important in India, where myopia rates are rapidly increasing.”

Dr. Kavita Joshi, a clinical researcher specializing in vision science, noted, “The reduction in axial length elongation is crucial because excessive elongation is linked to sight-threatening complications like retinal detachment and glaucoma later in adulthood.”

Context and Background

Myopia, or nearsightedness, occurs when the eye elongates excessively during childhood, causing distant objects to appear blurry. Its prevalence is rising worldwide with an estimated one-fifth of the global population projected to be myopic by 2030. High myopia (usually defined as -6.0 D or worse) substantially elevates the risk of irreversible vision loss.

Atropine, a well-known medication that relaxes eye muscles and dilates pupils, has been investigated extensively as a pharmacological intervention to slow myopia progression. Early studies used higher concentrations (1%) which were effective but often caused bothersome side effects such as light sensitivity and difficulty focusing. Recent research has focused on much lower doses (0.01% to 0.05%), seeking a safer yet effective alternative.

The AIIMS study aligns with international findings such as the LAMP (Low-concentration Atropine for Myopia Progression) study, which also identified 0.05% atropine as an optimal concentration for efficacy with minimal adverse effects in Asian children.

Implications for Public Health and Daily Life

Given the rising incidence of myopia, especially in urban areas with increased near work and reduced outdoor activities, the study’s findings provide an accessible intervention to help reduce disease burden. Slowing myopia progression in childhood may lower the risk of severe eye complications later:

• Reduced likelihood of retinal detachment, glaucoma, and myopic maculopathy

• Potential to decrease need for strong corrective lenses or surgical interventions

• Improvement in long-term vision health and quality of life

For parents and caregivers, incorporating low-dose atropine eyedrops under ophthalmologist supervision may complement existing recommendations such as encouraging outdoor play, limiting excessive screen time, and routine eye exams.

Limitations and Counterarguments

While the study presents robust evidence, several caveats remain:

• The trial was conducted over one year; longer-term effects and safety remain to be fully elucidated.

• A mild rebound effect, where myopia progression may accelerate after cessation of atropine, has been noted in other trials and requires further evaluation.

• Variation in individual response means some children may not experience significant benefits.

• Potential practical hurdles include access to quality-assured atropine formulations and adherence to nightly eye drop regimens.

Dr. Rahul Mehta, a leading ophthalmic researcher, cautions, “While promising, low-dose atropine is not a standalone solution. It should be part of a comprehensive myopia management strategy tailored to each child.”

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References